Abstract. Since February 2002, the Drug Resources Enhancement against AIDS and Malnutrition Program has provided highly active antiretroviral therapy (HAART) and immunologic and virologic monitoring free of charge. We conducted a cohort study of persons infected with human immunodeficiency virus in Mozambique. Only persons treated with HAART with available CD4 cell counts at baseline and ≥ 1 CD4 cell count after HAART were included. Survival analysis was applied to evaluate the prognostic value of CD4 cell counts measured at three months. Possible confounders were considered. A total of 753 persons who started HAART included; 59% were females. Median age was 34 years (range = 16-67 years), and the median CD4 cell count at baseline was 172 cells/mm 3 (interquartile range = 87-261 cells/mm 3 , range = 0-1,322 cells/mm 3 ). Overall, 105 persons (14%) died. Of these persons 54 (51%) developed AIDS before they died; 25 (3%) died during the first three months. After three months of therapy, the individual median CD4 cell count change from the baseline value was +101 cells/mm 3 (interquartile range = +27 to +187 cells/mm 3 , range = -723 to +310 cells/mm 3 ). A median CD4 increment of 100 cells/mm 3 in three months was associated with a mortality reduction of 50% compared with an increase of < 50 cells (relative hazard of death adjusted for baseline CD4 cell count = 0.54, 95% confidence interval = 0.30-0.95). A good initial response to HAART was associated with a significant reduction of mortality. This finding supports the effectiveness of HAART in resource-poor settings. 3 and a viral load > 55,000 copies/ mL). Furthermore, only persons with CD4 cell counts for the six months before the date of HAART initiation (i.e., baseline CD4 cell count) and with ≥ 1 CD4 cell count in the first three months after HAART inception were included in this study. Most persons who did not start HAART were females (64% versus 36% males) and maintained relatively high CD4 cell counts without starting antiretroviral therapy. Overall, they showed a median CD4 cell counts of 600 cells/mm 3 after three years and 500 cells/mm 3 after five years since the date of recruitment.
INTRODUCTION
Sub-Saharan Africa is region most affected by morbidity and mortality from infection with human immunodeficiency virus (HIV) and has approximately two-thirds of the world's HIV-infected persons. 1 Although the need is great, access to antiretroviral highly active antiretroviral therapy (HAART) treatment in most countries in this region and in other poorresource regions remains limited. However, great progress has been made in recent years. Up to now, almost 30% of persons estimated to be in need of treatment have been provided antiretroviral drugs. 2 Expanded access to antiretroviral drugs in this setting needs appropriate evaluation of the effectiveness of treatment programs.
As previously reported, early pessimism concerning effective delivery of HAART on a large scale has largely proven unfounded, 3 and high levels of treatment compliance and virologic suppression have been achieved in hospitalbased and community-based programs. [4] [5] [6] Moreover, metaanalyses of treatment cohorts have shown similar results for viral load suppression and CD4 cell count recovery among patients treated in high-income and resource-poor settings. 7, 8 However, early mortality after initiation of HAART was several-fold higher in resource-poor settings than in high-income settings. 7 Low baseline CD4 cell count, symptomatic disease (World Health Organization Stages 3 and 4), and low body mass index (BMI) have been reported to be independent risk factors of early mortality. 3 However, although early mortality (as measured four months after treatment initiation) was associated with patient characteristics at baseline, later mortality was only associated with the updated absolute CD4 cell counts at four months and with failure of viral load suppression, 9 which suggested that the response to HAART is the key long-term determinant of mortality among HIV-infected patients in Africa. 10 In this study, we analyzed the CD4 cell count decreases over time after initiation of treatment among HIV-infected persons in Mozambique and explored the role of early response to treatment (i.e., CD4 cell count decrease and viral load suppression) on longer-term mortality, taking into account possible confounders. 3 and a viral load > 55,000 copies/ mL). Furthermore, only persons with CD4 cell counts for the six months before the date of HAART initiation (i.e., baseline CD4 cell count) and with ≥ 1 CD4 cell count in the first three months after HAART inception were included in this study. Most persons who did not start HAART were females (64% versus 36% males) and maintained relatively high CD4 cell counts without starting antiretroviral therapy. Overall, they showed a median CD4 cell counts of 600 cells/mm 3 after three years and 500 cells/mm 3 after five years since the date of recruitment.
METHODS

Selection of participants.
Treatment and monitoring. HAART was defined as fixed-combination nevirapine-based regimens (stavudine/ azidothymidine, 2′,3′-dideoxy-3′-thiacytidine, nevirapine). Alanine aminotransferase, aspartate aminotransferase, and hemoglobin levels and clinical conditions were monitored weekly during the first month of HAART. CD4 cell counts were measured every three months and the viral load was measured every six months.
Statistical analysis. Statistical analyses included summaries of baseline characteristics of the study population and CD4+ cell counts (median, interquartile ranges [IQRs], ranges for continuous variables, and percentages for categorical variables). To plot CD4 cell count trends, the locally weighted scatterplot smoothing method was used 13 and relative fitted curves were presented.
To estimate immunologic response to HAART, median increments of CD4 cell counts from baseline (δ) were considered. Survival analysis was applied and considered increments of CD4 cell counts from baseline as the main variable of interest. Survival was estimated as time from initiation of HAART to time of death; follow-up was censored at the last visit before December 31, 2007. Analyses were repeated and censored persons who were lost to follow-up at the time when they were last known to be alive (usually the date of leaving the center mainly for dropout or transfer.) Univariable and multiple Cox models were applied to take into account possible confounders: CD4 cell count and HIV-1 load at baseline (within six months before starting HAART), hemoglobin level, BMI, age, and sex.
RESULTS
The study population included 753 HIV-positive persons fulfilling the inclusion criteria ( Table 1 ) . Median age at start of HAART of 34 years, and 59% of the participants were female. Median BMI was 20.7, and median hemoglobin level was 10.5 mg/dL. Median CD4+ cell count at baseline was < 200 cells/mm 3 (172 cells/mm 3 ), and the median log 10 HIV-1 load was 4.8 (i.e., 63,096 copies/mL).
Persons were followed-up for a median of 3 years (IQR = 1-4 years, range = 0.1-5 years); 71 (9%) persons moved and 50 (7%) dropped out. Acquired immunodeficiency syndrome developed in 142 (19%) patients; 105 patients (14% of the study population) died. Of these patients, 25 (3% of the population) died during the first 3 months of follow-up, 41 (5%) died between 4 and 12 months of follow-up, and 39 (5%) died after 12 months and up to 5 years after follow-up. Furthermore, 51% of the deaths fulfilled the criteria for diagnosis of acquired immunodeficiency syndrome.
Trends of CD4 cell counts after HAART. Trends of CD4 cell counts from 1 year before HAART up to 5 years after starting HAART are shown in Figure 1 , which highlights a clear increase in CD4+ cell counts over time. Descriptive statistics of increments of CD4 cell counts after three months from baseline are shown in Table 2 . A median increase of 101 CD4 cells and a median decrease in log 10 viral load of 2.6 was estimated after three months. A total of 85% of those who started HAART reached an undetectable viral load by three months.
Effect of response to HAART and survival. Curves showing progression to death according to the three-month CD4 cell count increments after HAART relative to baseline are shown in Figure 2 . Increments of ≥ 101 cells predicted less progression to death compared with increments between 50 and 100 or < 50 ( P = 0.071, by log-rank test).
Univariable and multiple Cox models are shown in Table 3 . A univariable Cox model showed that increments of CD4 cell counts from baseline (δ) after three months of HAART were associated with longer survival in five years of follow-up. Significant improvement in δ was observed when δ was considered as a categorical and continuous variable. When δ was used as a continuous variable, relative hazard [RH] of death × increments of 100 was 0.84 (95% confidence interval [CI] = 0.72-0.99). When δ was used as a categorical variable, significant reduction of mortality (approximately 50%) was observed for increments of at least 100 cells, and no effect on survival was observed for persons with low δ values (50-100 cells) when compared with increments of ≤ 49 cells. Results were confirmed in the multiple Cox model after considering variables significantly associated with survival (CD4 cell count and viral load at baseline, hemoglobin level , BMI, and sex) or censoring survival times of persons when they were last known to be alive (i.e., those lost to follow-up). The magnitude of estimates was confirmed for a subgroup with an HIV load < 400 after three months of HAART and adjusting for baseline HIV load, age, sex, and BMI, even if statistical significance was not obtained.
We performed an additional analysis that considered CD4 cell counts at the start of HAART (baseline CD4 cell count 
DISCUSSION
We evaluated the clinical and immunologic response to HAART in a cohort of HIV-infected persons from Mozambique. Mortality rates were relatively high in the first three months of treatment (approximately 3%), with an overall mortality rate of 14% by five years after treatment initiation.
The 12-month survival proportion in 18 studies of HIVinfected patients from Africa ranged from 0.74 to 0.92, with the greatest burden of mortality occurring during the initial months of HAART.
14 Mortality rates in the second year of HAART were much lower than those in the first year. This finding is consistent with results of longitudinal studies conducted in South Africa, which showed mortality rates of 19.1 deaths/100 person-years in the first four months, which decreased to 2.9 after 4 months and 1.3 after 1 year.
9, 10
Another study conducted in Senegal showed a similar trend, but substantial mortality was observed during 12-24 months of follow-up, with mortality rates of 12.5, 6.6, and 4.5 deaths/100 person-years in the first, second, and third year of treatment, respectively. 15 Because higher mortality rates are likely to be explained by lower rates of virologic suppression and associated poor immunologic recovery, it is of paramount importance to investigate CD4+ cell count trends and the role of decreases in CD4 cell counts in predicting survival after HAART initiation. This necessity is also a key point in creating mathematical models that predict epidemic patterns. 16 Our study also aimed to identify determinants of outcome. Median change in CD4+ cell counts three months after starting HAART was associated with survival. Participants with an increase of > 100 cells were 50% less likely to die than those who had an increase of < 50 cells.
F igure 1. Locally weighted scatterplot smoothing curve describing CD4 cell count trends six months before (CD4 cell count baseline) and after start of highly active antiretroviral therapy for one year, Mozambique. Early immunologic response was observed, with a median increase of approximately 100 CD4+ cells three months after starting HAART. These findings suggest that response to treatment in our cohort was at least as good as that observed in a European study, in which the median increase in CD4+ cell counts from baseline to six months after HAART initiation was 90 cells/mm 3 .
17
Among possible confounders included in the model, CD4 cell count at the start of HAART, hemoglobin level, BMI, and sex were also associated with the outcome. The HIV viral load was marginally associated after adjusting for the other variables and sex. Furthermore, we confirmed in our study cohort the importance of baseline CD4 cell counts as a prognostic marker of survival. We observed that the higher the CD4 cell count at baseline, the higher the reduction in mortality rates, again confirming the results of the European study. 17 In conclusion, our findings suggest that survival of HIVinfected persons treated with antiretroviral drugs in our study cohort was similar to that of European persons. Initial CD4 cell count and early response to treatment measured by an increase of CD4 cells in the first three months were predictors of longer survival. These data indicate that appropriate use of HAART in Africa may be as effective as that in industrialized countries and that CD4 cell count is a good indicator of response to treatment in difficult settings. 
